Please go to the PowerPak homepage
and select a course.
The Health-System Pharmacist’s Role in Providing the Most Effective Treatment for Patients with Hepatorenal Syndrome
February 16, 2021
February 16, 2022
This continuing education activity will highlight the health-system pharmacist’s role in providing treatment for patients with hepatorenal syndrome (HRS). The expert faculty will review the science, pathophysiology, and interplay between vasoconstrictor and vasodilator systems on the renal circulation in patients with hepatorenal syndrome type 1. Real-world data for new and emerging therapeutics in hospitalized patients with HRS type 1, including the use of vasoconstrictive agents, will be analyzed. The faculty will also discuss the safety, efficacy, and tolerability of current treatment agents for patients with type 1 HRS. This activity will provide learners with a better understanding of how to utilize the most effective treatment strategies to manage patients with hepatorenal syndrome in their pharmacy practice.
Hospital and health-system pharmacists involved in the therapeutic management and prevention of patients with HRS
- HRS: Pathophysiology, Presentation, and Potential Therapeutic Targets
- Review of New and Emerging Therapeutics in the Management of HRS Type 1
- The Hospital Pharmacist’s Role in Managing and Monitoring HRS: Guiding the Multidisciplinary, Interprofessional Care Team Through the Mine Field of Vasoactive Drug Therapy
- Review the science, pathophysiology, and interplay between vasoconstrictor and vasodilator systems on the renal circulation in patients with HRS type 1.
- Discuss the real-world data for new and emerging therapeutics in hospitalized patients with HRS type 1, including the use of vasoconstrictive agents, to improve treatment outcomes.
- Analyze the safety, efficacy, and tolerability of current treatment agents for patients with type 1 HRS.
John Fanikos, RPh, MBA
Assistant Professor of Clinical Pharmacy Practice
Massachusetts College of Pharmacy
Executive Director of Pharmacy
Brigham and Women’s Hospital
James F. Gilmore, PharmD, BCCCP, BCPS
Adult Critical Care and Emergency Department
Los Angeles, CA
Paul M. Szumita, PharmD, FCCM, FASHP, BCCCP, BCPS
Clinical Pharmacy Practice Manager
Program Director- PGY2 Critical Care Pharmacy Practice Residency
Brigham and Women’s Hospital
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
||Relationship Identified With
|John Fanikos, RPh, MBA
||Consultant/Advisor: Boehringer Ingelheim; AstraZeneca; Portola Pharmaceuticals, Inc.; Ipsen Pharmaceuticals
Grant/Research Support: Boehringer Ingelheim; Heron Therapeutics, Inc.
|James F. Gilmore, PharmD, BCCCP, BCPS
||Nothing to disclose
|Paul M. Szumita, PharmD, FCCM, FASHP, BCCCP, BCPS
||Nothing to disclose
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this continuing education activity for 1.25 CPE Contact Hours (0.125 CEUs) of continuing pharmacy education credit (UAN #JA4008190-0000-21-003-H01-P).
This activity has been supported by an independent educational grant from Mallinckrodt Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Mallinckrodt Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 50% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated. CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact firstname.lastname@example.org.
Provided by AcademicCME